BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
Rhea-AI Summary
BioCardia (NASDAQ:BCDA) will report 2025 financial results and provide a corporate update on a conference call on March 24, 2026 at 4:30 PM EDT. The event includes management remarks and a Q&A, with live webcast access and replay availability through June 24, 2026.
Registered participants receive dial-in details; domestic and international phone numbers and replay instructions are provided for listeners.
Positive
- None.
Negative
- None.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 call notice | Neutral | -3.0% | Scheduled Q3 2025 corporate update and financial results conference call. |
| Aug 06 | Q2 2025 call notice | Neutral | -5.5% | Announced Q2 2025 earnings conference call and corporate update timing. |
| May 09 | Q1 2025 call notice | Neutral | -0.3% | Scheduled Q1 2025 corporate update and financial results call. |
| Mar 21 | 2024 results & call | Neutral | +7.7% | Outlined 2024 financial results release and accompanying conference call. |
| Nov 06 | Q3 2024 call notice | Neutral | -1.2% | Announced Q3 2024 corporate update and financial results conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior BioCardia earnings/conference-call announcements around updates and results have produced mostly modest, often negative, single-day moves, with an average reaction of -0.49% across similar events.
Over the last few quarters, BioCardia has followed a consistent pattern of scheduling corporate update and financial results calls, such as Q1, Q2, and Q3 2025 events on May 14, August 11, and November 12, plus the 2024 results call on March 31, 2025. Price reactions to these scheduling announcements ranged from a 7.69% gain to mid-single-digit declines, indicating mixed sentiment. Today’s full-year 2025 call notice fits this established communication cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating to https://dpregister.com/sreg/10207584/1039b7a7360.
Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=5Vq7aAhd
A webcast replay of the call will be available approximately one hour after the end of the call through approximately June 24, 2026 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 7756290.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information visit www.biocardia.com.
MEDIA CONTACT:
Miranda Peto, Investor Relations
mpeto@biocardia.com
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120
